Company · founded 2008

NuvOx Pharma (United States)

Tucson, United States · nuvoxpharma.com

Manage this page

Citations, last 5 years: 42
Works, last 5 years: 13
h-index: 20
Scientists listed: 2
Grants since 2016: 16

Grants received

2025–2027 · research · R44

Liquid Biopsy in Glioblastoma Treated with Chemoradiation and an Oxygen Therapeutic

Katherine Havranek · NuvOx Pharma (United States) · funded by National Institutes of Health

$919.4k

2023–2026 · cooperative agreement · U44

Dodecafluoropentane emulsion (DDFPe), NanO2™ as Cerebroprotectant in Ischemic Stroke

Evan Charles Unger · NuvOx Pharma (United States) · funded by National Institutes of Health

$301.4k

2023–2026 · cooperative agreement · U44

Dodecafluoropentane emulsion (DDFPe), NanO2™ as Cerebroprotectant in Ischemic Stroke

Evan Charles Unger · NuvOx Pharma (United States) · funded by National Institutes of Health

$299.2k

2023–2026 · cooperative agreement · U44

Dodecafluoropentane emulsion (DDFPe), NanO2™ as Cerebroprotectant in Ischemic Stroke

Evan Charles Unger · NuvOx Pharma (United States) · funded by National Institutes of Health

$299.9k

2022–2026 · grant · BCRP

NanO2 Enhances Immunotherapy in Triple-Negative Breast Cancers

Evan Unger · NuvOx Pharma (United States) · funded by Congressionally Directed Medical Research Programs

$900.4k

2021–2024 · research · R41

NanO2 as a Cerebroprotectant in a tMCAO Stroke Model in Mice

Helena Willington Morrison · NuvOx Pharma (United States) · funded by National Institutes of Health

$478.1k

2017–2018 · research · R43

Dodecafluoropentane Prevents Ischemia Reperfusion Injury in Contemporary Acute Myocardial Infarction Management

Thomas R Porter · NuvOx Pharma (United States) · funded by National Institutes of Health

$317.7k

2017–2019 · research · R43

Development of a syringe/sonication device employed to administer DDFPe in the prehospital setting

Evan Charles Unger · NuvOx Pharma (United States) · funded by National Institutes of Health

$144kHemoglobin structure and function

2016–2018 · research · R41

Pancreatic Ductal Adenocarcinoma Targeted Ultrasound Contrast Agent Development

Evan Charles Unger · NuvOx Pharma (United States) · funded by National Institutes of Health

$297.8k

2016–2020 · research · R44

Pancreatic Ductal Adenocarcinoma Targeted Ultrasound Contrast Agent Development

Sanjiv S Gambhir · NuvOx Pharma (United States) · funded by National Institutes of Health

$963.6kUltrasound and Hyperthermia Applications

2016–2021 · research · R44

Pancreatic Ductal Adenocarcinoma Targeted Ultrasound Contrast Agent Development

Sanjiv S Gambhir · NuvOx Pharma (United States) · funded by National Institutes of Health

$1MUltrasound and Hyperthermia Applications

2016–2018 · research · R41

Targeted and Non-targeted Microbubbles for Pediatric Applications

Shelby Kutty · NuvOx Pharma (United States) · funded by National Institutes of Health

$243.2k

2016–2018 · research · R41

B7-H3-Targeted Contrast Agent for Ultrasonic Imaging of Breast Cancer

Jeremy Dahl · NuvOx Pharma (United States) · funded by National Institutes of Health

$298.8k

2010–2024 · research · R44

Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma

Baldassarre Stea · NuvOx Pharma (United States) · funded by National Institutes of Health

$492.6k

2010–2024 · research · R44

Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma

Baldassarre Stea · NuvOx Pharma (United States) · funded by National Institutes of Health

$1M

2010–2024 · research · R44

Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma

Baldassarre Stea · NuvOx Pharma (United States) · funded by National Institutes of Health

$1M